US007267820B2

(12) **United States Patent**
Vincent et al.

(10) **Patent No.: US 7,267,820 B2**
(45) **Date of Patent: Sep. 11, 2007**

(54) **NEUROTRANSMISSION DISORDERS**

(75) Inventors: **Angela Vincent**, Oxford (GB); **Werner Hoch**, Houston, TX (US)

(73) Assignees: **Isis Innovation Limited**, Oxford (GB); **Max-Planck Gesellschaft zur Foerderung der Wissenschaften e.V.**, Munich (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 506 days.

(21) Appl. No.: **10/311,575**

(22) PCT Filed: **Jun. 15, 2001**

(86) PCT No.: **PCT/GB01/02661**

§ 371 (c)(1),
(2), (4) Date: **Jun. 6, 2003**

(87) PCT Pub. No.: **WO01/96601**

PCT Pub. Date: **Dec. 20, 2001**

(65) **Prior Publication Data**

US 2004/0082010 A1 Apr. 29, 2004

(30) **Foreign Application Priority Data**

Jun. 16, 2000 (GB) 0014878.3

(51) **Int. Cl.**

A61K 39/395	(2006.01)
A61K 39/00	(2006.01)
A61K 38/00	(2006.01)
C07K 14/00	(2006.01)

(52) **U.S. Cl.** **424/130.1**; 424/184.1; 424/178.1; 514/2; 530/350

(58) **Field of Classification Search** ..... None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,814,478 A 9/1998 Bowen et al.

FOREIGN PATENT DOCUMENTS

WO WO99/10494 A 3/1999

OTHER PUBLICATIONS

Sisman, et al, 2004, Indian Pediatrics, 41:938-940.*

Blaes, F.,, Beeson, D., Plested, P., Lang, B., Vincent, A. IgG from seronegative myastheniagravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor *Ann Neurol*. Apr. 2000;47(4):504-10.

Brooks, E.B., Pachner, A.R., Drachman, D.B.,Kantor, F.S. A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in 'antibody-negative' myasthenia gravis. *J Neuroimmunol*. Jun. 1990;28(1):83-93.

Drachman, D.B. Myasthenia gravis. *N Engl J Med*. Jun. 23, 1994;330(25):1797-810.

Glass, D.J. et al. Agrin acts via a MuSK receptor complex. *Cell*. May 17, 1996;85(4):513-23.

Hoch W, et al., Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetycholine receptor antibodies. *Nat Med*. Mar. 2001;7(3):365-8.

Hoch, W., et al. Structural domains of agrin required for clustering of nicotinic acetylcholine receptors. *EMBO J*. Jun. 15, 1994;13(12):2814-21.

Hopf. C., Hoch, W. Heparin inhibits acetycholine receptor-aggregation at two distinct steps in the agrin-induced pathway. *Eur J Neurosci*. Jun. 1997;9(6):1170-7.

Hopf, C., Hoch, W. Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetycholine receptors and their aggregation on the surface of myotubes. *J Biol Chem*. Mar. 13, 1998;273(11):6467-73.

Hopf, C., Hoch, W. Tyrosine phosphorylation of the muscle-specific kinase is exclusively induced by acetycholine receptor-aggregating agrin fragments. *Eur J Biochem*. Apr. 15, 1998;253(2):382-9.

Lindstrom, J., Seybold,.M.E., Lennon, V.A., Whittingham, S., Duane, D.D., Antibody to acetycholine receptor in myasthenia gravis. prevalence, clinical correlates and diagnostic values. *Neurology*. Nov. 1976;26(11):1054-9.

Mier, A.K., Havard, C.W.H. Diaphragmatic myasthenia in mother and child. *Postgraduate Med J*. 611 725-727 (1985).

Mossman, S., Vincent, A., Newsom-Davis, J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. *Lancet*. Jan. 18, 1986;1(8473):116-9.

Riemersma S, Vincent A. Beeson D, Newland C, Brueton L, Huson S, Newsom-Davis J. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetalacetycholine receptor function. *J Clin Invest*. Nov. 15, 1996;98(10):2358-63.

Robertson, S.C., Tynan, J,A., Donoghue, D.J. RTK mutations and human syndromes: when good receptors turn bad. *Trends Genet*. Jun. 2000;16(6):265-71.

Sanes, J.R., et al., Development of the vertebrate neuromuscular junction. *Annual Review of Neuroscience 22*, 389-442 (1999).

Saunders, D.B., et al., Seronegative myasthenia gravis. *Neurology*. 48. S40-S45 (1997).

Taylor, S.I., Barbetti, F., Accili, D., Roth, J.,Gorden, P, Syndromes of autoi mmunity and hypoglycaemia. Autoantibodies directed against insulin and its receptor. *Endocrinol Metab Clin North Am*. Mar. 1989;18(1):123-43.

(Continued)

Primary Examiner—Eileen O'Hara
Assistant Examiner—Sandra Wegert
(74) *Attorney, Agent, or Firm*—Hamilton, Brook, Smith & Reynolds, P.C.

(57) **ABSTRACT**

There is disclosed a method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK). One such method comprises a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders. Also disclosed are kits for use in the diagnosis of neurotransmission and subsequent developmental disorders.

12 Claims, 6 Drawing Sheets